Citable company snapshot
IDEXX LABORATORIES INC /DE's latest SEC-sourced 2026-03-31 period shows $1.14B in revenue and $278.45M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $1.14B | $1.09B | +4.6% |
| xbrl:GrossProfit | Mar 31, 2026 | $722.74M | $658.11M | +9.8% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $362.59M | $315.61M | +14.9% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $278.45M | $248.19M | +12.2% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $266.25M | $355.76M | -25.2% |
| Free Cash Flow (computed) | Mar 31, 2026 | $234.26M | $326.33M | -28.2% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 5, 2026; accession 0000874716-26-000076.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
